This Article Full Text Full Text (PDF) All Versions of this Article: 107/15/2031    most recent 01.CIR.0000062682.40051.43v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lau, A. K. Articles by Stocker, R. Search for Related Content PubMed PubMed Citation Articles by Lau, A. K. Articles by Stocker, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angioplasty Antioxidants Related Collections Restenosis Animal models of human disease Smooth muscle proliferation and differentiation Oxidant stress Endothelium/vascular type/nitric oxide

(Circulation. 2003;107:2031.)
© 2003 American Heart Association, Inc.

Basic Science Reports

Probucol Promotes Functional Reendothelialization in Balloon-Injured Rabbit Aortas

Antony K. Lau, MBBS, FRACP; Steven B. Leichtweis, PhD; Peter Hume, BSc; Ryuichi Mashima, PhD; Jing Y. Hou, BSc; Xavier Chaufour, MD, PhD; Barbara Wilkinson, MSc; Nicholas H. Hunt, PhD; David S. Celermajer, MBBS, FRACP, PhD; Roland Stocker, PhD

From The Heart Research Institute (A.K.L., S.B.L., P.H., R.M., J.Y.H., D.S.C., R.S.), Departments of Vascular Surgery (X.C.), Pathology (N.H.H.), and Medicine (D.S.C.), University of Sydney, Skin and Cancer Foundation (B.W.), and University of New South Wales (R.S.), Sydney, Australia.

Correspondence to Roland Stocker, PhD, Centre for Vascular Research, School of Medical Sciences, Faculty of Medicine, University of New South Wales, UNSW Sydney 2052, Australia. E-mail r.stocker{at}unsw.edu.au

Background— Probucol remains the only conventional drug that reduces restenosis after coronary angioplasty. Apart from its weak cholesterol-lowering effect, probucol has antioxidant properties, but it remains unclear how this drug inhibits restenosis.

Methods and Results— Aortic balloon-injured New Zealand White rabbits were fed 2% (wt/wt) cholesterol-enriched or normal chow, with 0.75% (wt/wt) probucol (P) or without (controls, C) for 6 weeks. Endothelial denudation of the abdominal aorta was performed at week 3 with a 3F Fogarty embolectomy catheter. The arteries were harvested after week 6 and analyzed for histology, lipids and antioxidants, and endothelial regeneration and function. Probucol significantly decreased aortic intima-to-media ratio (cholesterol-fed: C, 1.10±0.08 versus P, 0.70±0.10; normal: C, 0.89±0.02 versus P, 0.83±0.05; P<0.05) and the numbers of proliferating intimal smooth muscle cells and lowered serum cholesterol without altering the proportion of aortic lipids that was oxidized. Probucol promoted endothelial regeneration in the injured aorta in cholesterol-fed rabbits (25% increase in reendothelialization, P<0.05) and in those on normal chow (37% increase, P<0.01). This was associated with both improved endothelial function as assessed by enhanced aortic ring relaxation and cGMP production in response to acetylcholine and decreased intimal thickening.

Conclusions— Probucol inhibits intimal thickening in balloon-damaged arteries of rabbits by promoting the regeneration of functional endothelium, without affecting the proportion of aortic lipids that was oxidized. This novel in vivo finding helps explain how probucol inhibits restenosis after coronary angioplasty and highlights potential new targets for therapeutic intervention.

Key Words: angioplasty • antioxidants • atherosclerosis • endothelium • restenosis

This article has been cited by other articles:

				R. Stocker and M. A. Perrella Heme Oxygenase-1: A Novel Drug Target for Atherosclerotic Diseases? Circulation, November 14, 2006; 114(20): 2178 - 2189. [Full Text] [PDF]

				B. J. Wu, K. Kathir, P. K. Witting, K. Beck, K. Choy, C. Li, K. D. Croft, T. A. Mori, D. Tanous, M. R. Adams, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging J. Exp. Med., April 17, 2006; 203(4): 1117 - 1127. [Abstract] [Full Text] [PDF]

				A. M Franks and S. F Gardner AGI-1067: A Novel Vascular Protectant for Prevention of Restenosis Ann. Pharmacother., January 1, 2006; 40(1): 66 - 73. [Abstract] [Full Text] [PDF]

				K. Choy, K. Beck, F. Y. Png, B. J. Wu, S. B. Leichtweis, S. R. Thomas, J. Y. Hou, K. D. Croft, T. A. Mori, and R. Stocker Processes Involved in the Site-Specific Effect of Probucol on Atherosclerosis in Apolipoprotein E Gene Knockout Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1684 - 1690. [Abstract] [Full Text] [PDF]

				P. K. Witting, B. J. Wu, M. Raftery, P. Southwell-Keely, and R. Stocker Probucol Protects against Hypochlorite-induced Endothelial Dysfunction: IDENTIFICATION OF A NOVEL PATHWAY OF PROBUCOL OXIDATION TO A BIOLOGICALLY ACTIVE INTERMEDIATE J. Biol. Chem., April 22, 2005; 280(16): 15612 - 15618. [Abstract] [Full Text] [PDF]

				R. S. Schwartz, N. A. Chronos, and R. Virmani Preclinical restenosis models and drug-eluting stents: Still important, still much to learn J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385. [Abstract] [Full Text] [PDF]

				Y.-M. Deng, B. J. Wu, P. K. Witting, and R. Stocker Probucol Protects Against Smooth Muscle Cell Proliferation by Upregulating Heme Oxygenase-1 Circulation, September 28, 2004; 110(13): 1855 - 1860. [Abstract] [Full Text] [PDF]